Restoring expression of tumour suppressor PTEN by engineered circular RNA‐enhanced Osimertinib sensitivity in non‐small cell lung cancer

Documenti analoghi

• The current therapeutic cancer vaccines landscape in non‐small cell lung cancer
  di: Shaoyi Chen, et al.
  Pubblicazione: (2024)
• Early postoperative plasma circulating tumour DNA for molecular residue disease detection and recurrence risk evaluation in surgical non‐small cell lung cancer
  di: Jie Tang, et al.
  Pubblicazione: (2024)
• The co‐location of CD14+APOE+ cells and MMP7+ tumour cells contributed to worse immunotherapy response in non‐small cell lung cancer
  di: Guangyu Fan, et al.
  Pubblicazione: (2024)
• Engineered lung cell targeting and SLC7A11 siRNA expressing bacterial extracellular vesicles impair the progression of none‐small cell lung cancer
  di: Xiao‐dan Wan, et al.
  Pubblicazione: (2025)
• CXCR5 and TLR4 signals synergistically enhance non‐small cell lung cancer progression
  di: Ji Hye Shin, et al.
  Pubblicazione: (2024)